Hep Drug to Shorten Hep C Treatment
Links shared publicly online about this topic
Regulators accept Merck drug for expedited review - Bloomberg
bloomberg.com — “WHITEHOUSE STATION, N.J. (AP) --" Drug developer Merck & Co. said Thursday U.S. and European regulators accepted its potential hepatitis C treatment boceprevir for expedited review.” View full resource at bloomberg.com
Most Recently Shared on January 10, 2011 at 3:43 pm By:
Raymond DuBois, MD, PhD Internist, Gastroenterologist, Health Executive, Physician, and Doctor
Regulators accept Merck drug (Hep C) for expedited review - http://t.co/IQkO5TJ
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Raymond DuBois, MD, PhD
Dr. Raymond N. DuBois is the Provost and Executive Vice President of The University of Texas M. D. Anderson Cancer Center. He is an internationally recognized cancer researcher who has numerous scholarly publications, research grants, and awards. His research has led the way for the development of new strategies for the prevention and possible treatment of colorectal cancer. Dr. DuBois is the President of the American Association for Cancer Research. Through his administrative, research, and leadership activities he supports initiatives that will have a global impact on cancer care, research, and outcomes for cancer patients.
Dr. DuBois obtained his education at The University of Texas Graduate System (1981, 1985) and at Texas A&M University (1977). He completed his clinical and postgraduate training at the Johns Hopkins Hospital in Baltimore (1991). His first faculty position was at Vanderbilt University School of Medicine in Nashville (1991) where he served until 2007 as Director of the Vanderbilt-Ingram Cancer Center before moving to Houston to assume his current position at The University of Texas M. D. Anderson Cancer Center.
Advertisement
